-transparent.png){kind=logo}
The effect of cotrimoxazole on the utilization of 6-mercaptopurine (6MP) was studied in a group of children receiving remission maintenance treatment for lymphoblastic leukaemia (ALL). This was done by measuring the level of an active metabolite of 6MP, 6-thioguanine nucleotide (6TGN), and comparing it both with the drug dose and with subsequent neutropenia in the presence or absence of concurrent cotrimoxazole. In children who were not taken cotrimoxazole, the concentration of 6TGN showed a significant positive correlation with the dose and a significant negative correlation with the absolute neutrophil count 2 weeks later. In those who were taking the antibiotic both these relationships were lost. This suggests that cotrimoxazole can interfere with both the absorption and the cytotoxicity of 6MP and may, in turn, alter its antileukaemic effect.
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
May 1994,
Lancet (London, England),
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
April 2017,
The Lancet. Oncology,
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
October 1997,
Medical and pediatric oncology,
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
July 1990,
Lancet (London, England),
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
April 1991,
Archives of disease in childhood,
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
October 2006,
Lancet (London, England),
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
January 1996,
Cancer chemotherapy and pharmacology,
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
October 1987,
Lancet (London, England),
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
December 2001,
Cancer treatment reviews,
C A Rees, and
L Lennard, and
J S Lilleyman, and
J L Maddocks
November 2017,
Leukemia research,
